[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.129.96. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Clinicopathologic Reports, Case Reports, and Small Case Series
June 2003

Detection of Lactate in the Human Vitreous Body Using Proton Magnetic Resonance Spectroscopy

Arch Ophthalmol. 2003;121(6):909-911. doi:10.1001/archopht.121.6.909

Proton magnetic resonance spectroscopy (1H-MRS) is an effective and useful technique for the metabolic analysis of tissues in vivo because it noninvasively identifies and quantifies tissue metabolites such as N-acetylaspartate, lactate, and choline.1 This technique is frequently used to assess the chemical composition of normal and pathologic brain tissue to investigate infarction, neoplasm, and mitochondrial disease.2 Similar application of 1H-MRS to ocular disease may prove beneficial for the noninvasive analysis of intraocular metabolism. Tissues of particular metabolic interest, such as the optic nerve and retina, are not amenable to direct study with 1H-MRS because of volume constraints and the high likelihood of contamination of the spectra by surrounding tissues. However, the relatively large size of the vitreous body should allow spectroscopic assessment of ocular metabolism. Lactate was the dominant metabolite detected in a study using 1H-MRS with a high-field (4.7-T) magnetic resonance imaging (MRI) scanner to determine the vitreous metabolic spectrum in healthy rabbits.3 The goal of our study was to assess the feasibility of performing 1H-MRS on the human vitreous in vivo and to determine if lactate is the dominant spectral resonance.

Report of Cases

Four healthy subjects and 1 with optic neuropathy (5 eyes) participated in the study with institutional review board approval. We used 1H-MRS(1.5-T Phillips NT clinical scanner; Phillips Medical System, Best, Holland) with a standard head coil to view the spectra of the vitreous. A set of high-resolution T1- and T2-weighted images from different orthogonal orientations were recorded to provide anatomical landmarks. To minimize spectrum contamination caused by partial volume effect from surrounding tissues, a single 10 × 10× 10-mm3 voxel was localized in the vitreous, using sagittal T1- and axial T2-weighted MR images (Figure 1). The spectra were acquired with single-voxel 1H-MRS using the point-resolved spectroscopy method with the following acquisition parameters: repetition time, 1500 milliseconds; echo time, 272 milliseconds; and sweep width, 1000 Hz. A 3-Hz line broadening was applied using a Guassian filter before Fourier transformation. After Fourier transformation, the spectra were phase corrected. No baseline correction was applied. The water line width was in the range of 12 to 15 Hz after the automatic first-order shimming (3-5 minutes). The average number of signals was typically 800. During acquisition, a foam pillow was placed around the head to minimize head movement, and the subject was instructed to look at a fixation target to minimize eye movement. Using the chemical shift selective suppression method, 90% water suppression was accomplished. No additional fat suppression was performed. The spectra were processed and analyzed using the scanner manufacturer's software. Lactate resonance was assigned by using the chemical shift of water as a reference and measuring the J-couple. Assignment of the lactate resonance was further confirmed by comparison with the spectrum of a phantom containing lactate solution.

Figure 1.
Representative sagittal T1-weighted(A) and T2-weighted (B) magnetic resonance imaging scout images for localization of anatomic landmarks, showing the 10-mm3 volume of interest in the left eye's vitreous body (A, white box; B, black box).

Representative sagittal T1-weighted(A) and T2-weighted (B) magnetic resonance imaging scout images for localization of anatomic landmarks, showing the 10-mm3 volume of interest in the left eye's vitreous body (A, white box; B, black box).

Vitreous spectra collected in each of the 5 vitreous bodies using 1H-MRS yielded 1 dominant resonance in addition to a residual water signal (Figure 2). The chemical shift of this resonance was 1.38 ppm, which was determined using the resonance of water at 4.68 ppm as an internal reference. This resonance was a doublet with a J-coupling of 9 Hz compared with the theoretical J-coupling constant of 7 Hz for the methyl proton of lactate.4 The chemical shift and characteristic J-coupling supported the assignment of the resonance to lactate. The spectrum obtained from the patient with optic neuropathy did not vary from the spectra of healthy subjects.

Figure 2.
Lactate was identified as the dominant resonance in the vitreous spectrum using proton magnetic resonance spectroscopy with a chemical shift of 1.38 ppm and a J-coupling constant of 9 Hz.

Lactate was identified as the dominant resonance in the vitreous spectrum using proton magnetic resonance spectroscopy with a chemical shift of 1.38 ppm and a J-coupling constant of 9 Hz.

Comment

Lactate is present in the human vitreous at a higher concentration than in other tissues, likely reflecting substantial normal retinal aerobic and anaerobic glucose metabolism.5,6 The proximity of the vitreous to the optic nerve and retina allows for diffusion of lactate into the vitreous. Elevated lactate concentration in the optic nerve and/or retina is generally reflected in the vitreous.

Vascular insults, such as central retinal artery or vein occlusion, anterior ischemic optic neuropathy, ocular ischemic syndrome, or impairment of the mitochondrial respiratory chain found in mitochondrial diseases, may cause decreased oxygenation and elevated lactate production.7 The correlation of lactate production with the adequacy of perfusion and oxygenation of the retina and optic nerve suggests that it may be possible to use lactate as a molecular marker to evaluate retinal and optic nerve metabolism in ocular disease and monitor pathologic changes in the human vitreous. Elevated levels of brain lactate have been detected using 1H-MRS in patients with stroke, myoclonic epilepsy with ragged red fibers, or mitochondrial encephalopathy with lactic acidosis and strokelike episodes.1,8

Our observation of lactate as the dominant resonance in the vitreous spectra in 5 human eyes in vivo suggests that characterization of the localized human vitreous spectrum in vivo is feasible using 1H-MRS. Similar detection of lactate in the human vitreous body was reported with the application of 1H-MRS in patients with glaucoma. Technical obstacles encountered in 1H-MRS application to the human vitreous include low sensitivity in detecting metabolites with a concentration lower than 10 mmol/L using a 1.5-T MRI scanner, and interference from the water signal (approximately 55 mmol/L), which requires efficient water suppression. Nevertheless, the in vitro vitreous lactate concentration of 7.8 mmol/L (calculated from a vitreous lactate concentration of 70 mg/d L using a conversion factor of 0.1110) suggests that it is possible to detect lactate in healthy eyes.6 Additionally, the application of a high-field 3-T MRI scanner should improve the sensitivity of 1H-MRS in studying the vitreous lactate because the signal intensity increases proportionally as the field strength increases.

Absolute quantification of the vitreous lactate concentration with 1H-MRS is necessary for maximum clinical applicability. Quantification should be possible through the use of an internal reference such as the unsuppressed water signal acquired from the same volume of interest as the metabolite to be quantified.1

Using 1H-MRS to determine the normal human vitreous spectra and lactate concentration is the initial step in applying this technology to human ocular disease. Application of 1H-MRS to the human vitreous in vivo may provide a noninvasive method of evaluating and following retinal and optic nerve metabolism in healthy eyes as well as those with ocular disease.

Back to top
Article Information

This study was supported in part by a departmental grant (Department of Ophthalmology, Emory Eye Center) from Research to Prevent Blindness, Inc, New York, NY, and by core grant P30-EY06360 (Department of Ophthalmology, Emory Eye Center) from the National Institute of Health, Bethesda, Md. Dr Newman is the recipient of a Lew R. Wasserman Merit Award from Research to Prevent Blindness.

Corresponding author and reprints: Nancy J. Newman, MD, Neuro-ophthalmology Unit, Emory Eye Center, 1365-B Clifton Rd NE, Atlanta, GA 30322 (e-mail: ophtnjn@emory.edu).

References
1.
Constantinidis  I MRS methodology. In:Henry  TDuncan  JBerkovic  Seds.Functional Imaging in the Epilepsies Philadelphia, Pa Lippincott Williams &Wilkins2000;235- 246
2.
Rudkin  TArnold  D Proton magnetic resonance spectroscopy for the diagnosis and management of cerebral disorders. Arch Neurol. 1999;56919- 926Article
3.
Berkowitz  BABansal  NWilson  CA Non-invasive measurement of steady-state vitreous lactate concentration. NMR Biomed. 1994;7263- 268Article
4.
Cendes  F Proton MRS: lactate. In:Henry  TDuncan  JBerkovic  Seds.Functional Imaging in the Epilepsies Philadelphia, Pa Lippincott Williams &Wilkins2000;247- 251
5.
Poitry-Yamate  CLPoitry  STsacopoulos  M Lactate released by Muller glial cells is metabolized by photoreceptors from mammalian retina. J Neurosci. 1995;155179- 5191
6.
Sebag  J The vitreous. In:Hart  Wed.Adler's Physiology of the Eye. 9th St Louis, Mo Mosby-Year Book Inc1992;268- 340
7.
Doberstein  CFineman  IHovda  DAMartin  NAKeenly  LBecker  DP Metabolic alterations accompany ionic disturbances and cellular swelling during a hypoxic insult to the retina: an in vitro study. Acta Neurochir Suppl (Wien). 1994;6041- 44
8.
Pavlakis  SGKingsley  PBKaplan  GPStacpoole  PWO'Shea  MLustbader  D Magnetic resonance spectroscopy: use in monitoring MELAS treatment. Arch Neurol. 1998;55849- 852Article
×